HMM304 - Therapeutic Development
Unit details
Year | 2025 unit information |
---|---|
Enrolment modes: | Trimester 2: Burwood (Melbourne), Waurn Ponds (Geelong) |
Credit point(s): | 1 |
EFTSL value: | 0.125 |
Unit Chair: | Trimester 2: Craig Smith |
Prerequisite: | HMM202 or SLE212 |
Corequisite: | Nil |
Incompatible with: | Nil |
Educator-facilitated (scheduled) learning activities - on-campus unit enrolment: | 1 x 2 hour live online lecture in weeks 1-11 |
Typical study commitment: | Students will on average spend 150 hours over the teaching period undertaking the teaching, learning and assessment activities for this unit. This will include educator guided online learning activities within the unit site. |
Content
This unit describes how therapeutics such as pharmacological drugs are discovered and developed, in order to treat disease. Non-targeted and targeted drug discovery is discussed, in addition to target validation, in the contexts of big pharmaceutical companies and smaller research laboratories. Drug development strategies and pipelines that are adopted by big pharmaceutical companies are then described, including the chemical optimisation of lead compounds, pre-clinical and clinical trials, commercialisation and post-market considerations.
Learning Outcomes
ULO | These are the Unit Learning Outcomes (ULOs) for this unit. At the completion of this unit, successful students can: | Alignment to Deakin Graduate Learning Outcomes (GLOs) |
---|---|---|
ULO1 | Explain the principles of drug discovery and development and have a basic understanding of its role in society. | GLO1: Discipline-specific knowledge and capabilities |
ULO2 | Be able to complete a critical evaluation of the drug development process, using case study examples. | GLO1: Discipline-specific knowledge and capabilities |
ULO3 | Use digital and non-digital means to search for current and relevant supporting scholarly evidence and make clear and cohesive arguments that are correctly referenced, within the discipline of therapeutic development. | GLO2: Communication |
ULO4 | Present information in a clear, accurate and concise manner using various means (e.g., written report) to specialists and non-specialists within the discipline of drug development. | GLO2: Communication |
Assessment
Trimester 2:Assessment description | Student output | Grading and weighting (% total mark for unit) | Indicative due week |
---|---|---|---|
Assessment 1: Poster assignment | Poster and recorded description | 35% |
|
Assessment 2: Oral presentation | Preparation and oral presentation of PowerPoint slides | 35% |
|
Assessment 3: End-of-unit Assessment: online test | 90 minutes | 30% |
|
The assessment due weeks provided may change. The Unit Chair will clarify the exact assessment requirements, including the due date, at the start of the teaching period.
Learning resource
The texts and reading list for HMM304 can be found via the University Library.
Note: Select the relevant trimester reading list. Please note that a future teaching period's reading list may not be available until a month prior to the start of that teaching period so you may wish to use the relevant trimester's prior year reading list as a guide only.
Unit Fee Information
Fees and charges vary depending on the type of fee place you hold, your course, your commencement year, the units you choose to study and their study discipline, and your study load.
Tuition fees increase at the beginning of each calendar year and all fees quoted are in Australian dollars ($AUD). Tuition fees do not include textbooks, computer equipment or software, other equipment or costs such as mandatory checks, travel and stationery.
For further information regarding tuition fees, other fees and charges, invoice due dates, withdrawal dates, payment methods visit our Current Students website.